Non-small cell lung cancer · line 1 · Durvalumab consolidation post-CRT (NSCLC stage III unresectable)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-DURVA-CONSOLIDATION-PACIFIC |
| ID | IND-NSCLC-STAGE-III-PACIFIC |
|---|---|
| Type | Indication |
| Status | status not declared |
| Diseases | DIS-NSCLC |
| Sources | SRC-ESMO-NSCLC-EARLY-2024 SRC-NCCN-NSCLC-2025 |
Notes
Standard for stage III unresectable post-concurrent CRT. Pneumonitis G≥2 at end of CRT excludes durva initiation.
Used By
No reverse references found in the YAML corpus.